Print

Purpose

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: - This event-driven study will have variable duration of approximately 40 months for the first participant being randomized and approximately 20 months for the last participant randomized. - The study intervention duration will vary ranging from approximately 12 to 40 months. - The assessment of scheduled visits will include 1 common end of study [EOS] visit and 3 follow-up visits) with a visit frequency of every 4 weeks for the first 6 months and then every 3 months.

Condition

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • The participant must have been diagnosed with RMS according to the 2017 revision of the McDonald diagnostic criteria. - The participant has an EDSS score ≤5.5 at the first visit (Screening Visit) - The participant must have at least 1 of the following prior to screening: - ≥1 documented relapse within the previous year OR - ≥2 documented relapses within the previous 2 years, OR - ≥1 documented Gd enhancing lesion on an MRI scan within the previous year. - Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria

  • The participant has been diagnosed with PPMS according to the 2017 revision of the McDonald diagnostic criteria - The participant has a history of infection or may be at risk for infection: - The presence of psychiatric disturbance or substance abuse. - History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment. - History or current hypogammaglobulinemia defined by values below the lower limit of normal (LLN). - A history or presence of disease that can mimic MS symptoms, such as, but not limited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus, Sjogren's syndrome, acute disseminated encephalomyelitis, and myasthenia gravis. - The participant has had a relapse in the 30 days prior to randomization. - The participant has contraindication for MRI, ie, presence of pacemaker, metallic implants in high risk areas (ie, artificial heart valves, aneurysm/vessel clips), presence of metallic material (eg, shrapnel) in high risk areas, known history of allergy to any contrast medium, or history of claustrophobia that would prevent completion of all protocol scheduled MRI scans. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
Double-dummy

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Frexalimab 		Participants will receive Frexalimab infusion and placebo tablet.
  • Drug: Frexalimab
    SAR441344 Solution for IV infusion
  • Drug: Placebo tablet
    Oral tablet
  • Drug: MRI contrast-enhancing agents
    IV, as per respective label
  • Drug: Cholestyramine
    oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
  • Drug: Activated charcoal
    oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
Active Comparator
Teriflunomide 		Participants will receive teriflunomide tablet and placebo infusion.
  • Drug: Teriflunomide
    Aubagio oral tablet
  • Drug: Placebo infusion
    Solution for IV infusion
  • Drug: MRI contrast-enhancing agents
    IV, as per respective label
  • Drug: Cholestyramine
    oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
  • Drug: Activated charcoal
    oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.

Recruiting Locations

University of Kansas Medical Center - Site Number : 8400084
Kansas City, Kansas 66103

More Details

Status
Recruiting
Sponsor
Sanofi

Study Contact

Trial Transparency email recommended (Toll free number for US & Canada)
800-633-1610
contact-us@sanofi.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.